Skip to main content
PMC home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1995 Oct;116(3):2081–2089. doi: 10.1111/j.1476-5381.1995.tb16415.x

A re-evaluation of the role of alpha 2-adrenoceptors in the anxiogenic effects of yohimbine, using the selective antagonist delequamine in the rat.

W S Redfern 1, A Williams 1
PMCID: PMC1908953  PMID: 8640349

Abstract

1. The acute behavioural effects of the alpha2-adrenoceptor antagonists, yohimbine, idazoxan and delequamine (RS-15385-197) were compared in two tests of exploratory behaviour in the rat, operated in tandem. These were the elevated X-maze test (5 min) and a modified holeboard test (12 min), which comprised a holeboard arena with a small roof in one corner as a 'refuge'. Rats were first placed into this corner, thus enabling measurements of initial emergence latency and the number of forays. The experiments were always done with a concomitant vehicle control group, with 10-12 rats per group, and with the treatment blinded. 2. In order to validate the tests, the effects of representatives of four classes of psychoactive agents were examined, viz. picrotoxin (anxiogenic), chlordiazepoxide (anxiolytic), (+)-amphetamine (stimulant) and diphenhydramine (sedative). The modified holeboard tended to be more sensitive than the measurement of total arm entries in the elevated X-maze at detecting drug effects on exploratory behaviour, but unlike the X-maze it could not clearly identify each class of agent. Thus, picrotoxin (5 mg kg(-1), i.p.) reduced total arm entries and open arm exploration in the X-maze (P<0.02) and suppressed most measures of activity in the holeboard (P<0.05); chlordiazepoxide (7.5 mg kg(-1), i.p.) increased total arm entries and open arm exploration (P<0.02) in the X-maze, without clear-cut effects in the holeboard; (+)-amphetamine (1 mg kg(-1), i.p.) had no significant effects in the X-maze, but increased most holeboard activities (P<0.05), and diphenhydramine (30 mg kg(-1), i.p.) reduced total arm entries in the X-maze (P<0.002) and hole exploration in the holeboard (P<0.05).

Full text

PDF
2089

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arthur J. M., Casañas S. J., Raymond J. R. Partial agonist properties of rauwolscine and yohimbine for the inhibition of adenylyl cyclase by recombinant human 5-HT1A receptors. Biochem Pharmacol. 1993 Jun 9;45(11):2337–2341. doi: 10.1016/0006-2952(93)90208-e. [DOI] [PubMed] [Google Scholar]
  2. Baldwin H. A., Johnston A. L., File S. E. Antagonistic effects of caffeine and yohimbine in animal tests of anxiety. Eur J Pharmacol. 1989 Jan 10;159(2):211–215. doi: 10.1016/0014-2999(89)90709-7. [DOI] [PubMed] [Google Scholar]
  3. Berridge T. L., Gadie B., Roach A. G., Tulloch I. F. alpha 2-Adrenoceptor agonists induced mydriasis in the rat by an action within the central nervous system. Br J Pharmacol. 1983 Mar;78(3):507–515. doi: 10.1111/j.1476-5381.1983.tb08810.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Brown C. M., MacKinnon A. C., Redfern W. S., Hicks P. E., Kilpatrick A. T., Small C., Ramcharan M., Clague R. U., Clark R. D., MacFarlane C. B. The pharmacology of RS-15385-197, a potent and selective alpha 2-adrenoceptor antagonist. Br J Pharmacol. 1993 Feb;108(2):516–525. doi: 10.1111/j.1476-5381.1993.tb12834.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Carruthers S. G., Shoeman D. W., Hignite C. E., Azarnoff D. L. Correlation between plasma diphenhydramine level and sedative and antihistamine effects. Clin Pharmacol Ther. 1978 Apr;23(4):375–382. doi: 10.1002/cpt1978234375. [DOI] [PubMed] [Google Scholar]
  6. Charney D. S., Woods S. W., Goodman W. K., Heninger G. R. Neurobiological mechanisms of panic anxiety: biochemical and behavioral correlates of yohimbine-induced panic attacks. Am J Psychiatry. 1987 Aug;144(8):1030–1036. doi: 10.1176/ajp.144.8.1030. [DOI] [PubMed] [Google Scholar]
  7. Charney D. S., Woods S. W., Heninger G. R. Noradrenergic function in generalized anxiety disorder: effects of yohimbine in healthy subjects and patients with generalized anxiety disorder. Psychiatry Res. 1989 Feb;27(2):173–182. doi: 10.1016/0165-1781(89)90132-7. [DOI] [PubMed] [Google Scholar]
  8. Cheng C. H., Costall B., Ge J., Naylor R. J. The profiles of interaction of yohimbine with anxiolytic and putative anxiolytic agents to modify 5-HT release in the frontal cortex of freely-moving rats. Br J Pharmacol. 1993 Nov;110(3):1079–1084. doi: 10.1111/j.1476-5381.1993.tb13924.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Chopin P., Pellow S., File S. E. The effects of yohimbine on exploratory and locomotor behaviour are attributable to its effects at noradrenaline and not at benzodiazepine receptors. Neuropharmacology. 1986 Jan;25(1):53–57. doi: 10.1016/0028-3908(86)90058-4. [DOI] [PubMed] [Google Scholar]
  10. Clark R. D., Repke D. B., Kilpatrick A. T., Brown C. M., MacKinnon A. C., Clague R. U., Spedding M. (8a alpha,12a alpha,13a alpha)-5,8,8a,9,10,11,12,12a,13,13a-decahydro- 3-methoxy-12-(methylsulfonyl)-6H-isoquino[2,1-g][1,6]naphthyridi ne, a potent and highly selective alpha 2-adrenoceptor antagonist. J Med Chem. 1989 Sep;32(9):2034–2036. doi: 10.1021/jm00129a002. [DOI] [PubMed] [Google Scholar]
  11. Davis M., Redmond D. E., Jr, Baraban J. M. Noradrenergic agonists and antagonists: effects on conditioned fear as measured by the potentiated startle paradigm. Psychopharmacology (Berl) 1979 Oct;65(2):111–118. doi: 10.1007/BF00433036. [DOI] [PubMed] [Google Scholar]
  12. Dawson G. R., Tricklebank M. D. Use of the elevated plus maze in the search for novel anxiolytic agents. Trends Pharmacol Sci. 1995 Feb;16(2):33–36. doi: 10.1016/s0165-6147(00)88973-7. [DOI] [PubMed] [Google Scholar]
  13. Dietl H., Sinha J. N., Philippu A. Presynaptic regulation of the release of catecholamines in the cat hypothalamus. Brain Res. 1981 Mar 9;208(1):213–218. doi: 10.1016/0006-8993(81)90635-1. [DOI] [PubMed] [Google Scholar]
  14. Ferrari F., Tartoni P. L., Mangiafico V. B-HT 920 antagonizes rat neophobia in the X-maze test: a comparative study with other drugs active on adrenergic and dopaminergic receptors. Arch Int Pharmacodyn Ther. 1989 Mar-Apr;298:7–14. [PubMed] [Google Scholar]
  15. Feuerstein T. J., Mutschler A., Lupp A., Van Velthoven V., Schlicker E., Göthert M. Endogenous noradrenaline activates alpha 2-adrenoceptors on serotonergic nerve endings in human and rat neocortex. J Neurochem. 1993 Aug;61(2):474–480. doi: 10.1111/j.1471-4159.1993.tb02148.x. [DOI] [PubMed] [Google Scholar]
  16. File S. E. Aversive and appetitive properties of anxiogenic and anxiolytic agents. Behav Brain Res. 1986 Sep;21(3):189–194. doi: 10.1016/0166-4328(86)90236-6. [DOI] [PubMed] [Google Scholar]
  17. File S. E., Lister R. G. Do the reductions in social interaction produced by picrotoxin and pentylenetetrazole indicate anxiogenic actions? Neuropharmacology. 1984 Jul;23(7A):793–796. doi: 10.1016/0028-3908(84)90113-8. [DOI] [PubMed] [Google Scholar]
  18. File S. E., Pellow S., Wilks L. The sedative effects of CL 218,872, like those of chlordiazepoxide, are reversed by benzodiazepine antagonists. Psychopharmacology (Berl) 1985;85(3):295–300. doi: 10.1007/BF00428190. [DOI] [PubMed] [Google Scholar]
  19. File S. E. The contribution of behavioural studies to the neuropharmacology of anxiety. Neuropharmacology. 1987 Jul;26(7B):877–886. doi: 10.1016/0028-3908(87)90065-7. [DOI] [PubMed] [Google Scholar]
  20. File S. E. What can be learned from the effects of benzodiazepines on exploratory behavior? Neurosci Biobehav Rev. 1985 Spring;9(1):45–54. doi: 10.1016/0149-7634(85)90031-4. [DOI] [PubMed] [Google Scholar]
  21. Garratt J. C., Crespi F., Mason R., Marsden C. A. Effects of idazoxan on dorsal raphe 5-hydroxytryptamine neuronal function. Eur J Pharmacol. 1991 Jan 25;193(1):87–93. doi: 10.1016/0014-2999(91)90204-4. [DOI] [PubMed] [Google Scholar]
  22. Gertz B. J., Vlasses P. H., Rocci M. L., Jr, Coker L. D., Williams V., Bjornsson T. D., Jones K. H. Clinical evaluation of a benzofuroquinolizine alpha 2-adrenoceptor antagonist. Clin Pharmacol Ther. 1989 Nov;46(5):566–575. doi: 10.1038/clpt.1989.187. [DOI] [PubMed] [Google Scholar]
  23. Gobbi M., Frittoli E., Mennini T. Further studies on alpha 2-adrenoceptor subtypes involved in the modulation of [3H]noradrenaline and [3H]5-hydroxytryptamine release from rat brain cortex synaptosomes. J Pharm Pharmacol. 1993 Sep;45(9):811–814. doi: 10.1111/j.2042-7158.1993.tb05691.x. [DOI] [PubMed] [Google Scholar]
  24. Guy A. P., Gardner C. R. Pharmacological characterisation of a modified social interaction model of anxiety in the rat. Neuropsychobiology. 1985;13(4):194–200. doi: 10.1159/000118187. [DOI] [PubMed] [Google Scholar]
  25. HOLMBERG G., GERSHON S. Autonomic and psychic effects of yohimbine hydrochloride. Psychopharmacologia. 1961;2:93–106. doi: 10.1007/BF00592678. [DOI] [PubMed] [Google Scholar]
  26. Handley S. L., McBlane J. W. An assessment of the elevated X-maze for studying anxiety and anxiety-modulating drugs. J Pharmacol Toxicol Methods. 1993 Jun;29(3):129–138. doi: 10.1016/1056-8719(93)90063-k. [DOI] [PubMed] [Google Scholar]
  27. Handley S. L., Mithani S. Effects of alpha-adrenoceptor agonists and antagonists in a maze-exploration model of 'fear'-motivated behaviour. Naunyn Schmiedebergs Arch Pharmacol. 1984 Aug;327(1):1–5. doi: 10.1007/BF00504983. [DOI] [PubMed] [Google Scholar]
  28. Heninger G. R., Charney D. S., Price L. H. alpha 2-Adrenergic receptor sensitivity in depression. The plasma MHPG, behavioral, and cardiovascular responses to yohimbine. Arch Gen Psychiatry. 1988 Aug;45(8):718–726. doi: 10.1001/archpsyc.1988.01800320028003. [DOI] [PubMed] [Google Scholar]
  29. Iversen S. D. 5-HT and anxiety. Neuropharmacology. 1984 Dec;23(12B):1553–1560. doi: 10.1016/0028-3908(84)90099-6. [DOI] [PubMed] [Google Scholar]
  30. Johnston A. L., File S. E. Yohimbine's anxiogenic action: evidence for noradrenergic and dopaminergic sites. Pharmacol Biochem Behav. 1989 Jan;32(1):151–156. doi: 10.1016/0091-3057(89)90225-6. [DOI] [PubMed] [Google Scholar]
  31. Kauppila T., Tanila H., Carlson S., Taira T. Effects of atipamezole, a novel alpha 2-adrenoceptor antagonist, in open-field, plus-maze, two compartment exploratory, and forced swimming tests in the rat. Eur J Pharmacol. 1991 Nov 26;205(2):177–182. doi: 10.1016/0014-2999(91)90817-a. [DOI] [PubMed] [Google Scholar]
  32. Krystal J. H., McDougle C. J., Woods S. W., Price L. H., Heninger G. R., Charney D. S. Dose-response relationship for oral idazoxan effects in healthy human subjects: comparison with oral yohimbine. Psychopharmacology (Berl) 1992;108(3):313–319. doi: 10.1007/BF02245117. [DOI] [PubMed] [Google Scholar]
  33. Lorenz W., Lomasney J. W., Collins S., Regan J. W., Caron M. G., Lefkowitz R. J. Expression of three alpha 2-adrenergic receptor subtypes in rat tissues: implications for alpha 2 receptor classification. Mol Pharmacol. 1990 Nov;38(5):599–603. [PubMed] [Google Scholar]
  34. MacKinnon A. C., Kilpatrick A. T., Kenny B. A., Spedding M., Brown C. M. [3H]-RS-15385-197, a selective and high affinity radioligand for alpha 2-adrenoceptors: implications for receptor classification. Br J Pharmacol. 1992 Aug;106(4):1011–1018. doi: 10.1111/j.1476-5381.1992.tb14449.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. MacKinnon A. C., Spedding M., Brown C. M. Alpha 2-adrenoceptors: more subtypes but fewer functional differences. Trends Pharmacol Sci. 1994 Apr;15(4):119–123. doi: 10.1016/0165-6147(94)90048-5. [DOI] [PubMed] [Google Scholar]
  36. Mattila M., Seppala T., Mattila M. J. Anxiogenic effect of yohimbine in healthy subjects: comparison with caffeine and antagonism by clonidine and diazepam. Int Clin Psychopharmacol. 1988 Jul;3(3):215–229. doi: 10.1097/00004850-198807000-00003. [DOI] [PubMed] [Google Scholar]
  37. Maura G., Bonanno G., Raiteri M. Presynaptic alpha 2-adrenoceptors mediating inhibition of noradrenaline and 5-hydroxytryptamine release in rat cerebral cortex: further characterization as different alpha 2-adrenoceptor subtypes. Naunyn Schmiedebergs Arch Pharmacol. 1992 Apr;345(4):410–416. doi: 10.1007/BF00176618. [DOI] [PubMed] [Google Scholar]
  38. Merlo Pich E., Samanin R. A two-compartment exploratory model to study anxiolytic/anxiogenic effects of drugs in the rat. Pharmacol Res. 1989 Sep-Oct;21(5):595–602. doi: 10.1016/1043-6618(89)90201-6. [DOI] [PubMed] [Google Scholar]
  39. Moser P. C. An evaluation of the elevated plus-maze test using the novel anxiolytic buspirone. Psychopharmacology (Berl) 1989;99(1):48–53. doi: 10.1007/BF00634451. [DOI] [PubMed] [Google Scholar]
  40. Pellow S., Chopin P., File S. E. Are the anxiogenic effects of yohimbine mediated by its action at benzodiazepine receptors? Neurosci Lett. 1985 Mar 22;55(1):5–9. doi: 10.1016/0304-3940(85)90303-9. [DOI] [PubMed] [Google Scholar]
  41. Pellow S., Chopin P., File S. E., Briley M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods. 1985 Aug;14(3):149–167. doi: 10.1016/0165-0270(85)90031-7. [DOI] [PubMed] [Google Scholar]
  42. Rasmussen K., Jacobs B. L. Single unit activity of locus coeruleus neurons in the freely moving cat. II. Conditioning and pharmacologic studies. Brain Res. 1986 Apr 23;371(2):335–344. doi: 10.1016/0006-8993(86)90371-9. [DOI] [PubMed] [Google Scholar]
  43. Redfern W. S., MacKinnon A. C., Brown C. M., Martin A. B., Kilpatrick A. T., Clague R. U., Spedding M. Modulation of central noradrenergic function by RS-15385-197. Br J Pharmacol. 1993 Feb;108(2):526–533. doi: 10.1111/j.1476-5381.1993.tb12835.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Rosin D. L., Zeng D., Stornetta R. L., Norton F. R., Riley T., Okusa M. D., Guyenet P. G., Lynch K. R. Immunohistochemical localization of alpha 2A-adrenergic receptors in catecholaminergic and other brainstem neurons in the rat. Neuroscience. 1993 Sep;56(1):139–155. doi: 10.1016/0306-4522(93)90569-2. [DOI] [PubMed] [Google Scholar]
  45. Ruffolo R. R., Jr, Nichols A. J., Stadel J. M., Hieble J. P. Pharmacologic and therapeutic applications of alpha 2-adrenoceptor subtypes. Annu Rev Pharmacol Toxicol. 1993;33:243–279. doi: 10.1146/annurev.pa.33.040193.001331. [DOI] [PubMed] [Google Scholar]
  46. Southwick S. M., Krystal J. H., Morgan C. A., Johnson D., Nagy L. M., Nicolaou A., Heninger G. R., Charney D. S. Abnormal noradrenergic function in posttraumatic stress disorder. Arch Gen Psychiatry. 1993 Apr;50(4):266–274. doi: 10.1001/archpsyc.1993.01820160036003. [DOI] [PubMed] [Google Scholar]
  47. Söderpalm B., Engel J. A. Alpha 2-adrenoceptor antagonists potentiate the anticonflict and the rotarod impairing effects of benzodiazepines. J Neural Transm. 1989;76(3):191–204. doi: 10.1007/BF01260504. [DOI] [PubMed] [Google Scholar]
  48. Tao R., Hjorth S. Alpha 2-adrenoceptor modulation of rat ventral hippocampal 5-hydroxytryptamine release in vivo. Naunyn Schmiedebergs Arch Pharmacol. 1992 Feb;345(2):137–143. doi: 10.1007/BF00165728. [DOI] [PubMed] [Google Scholar]
  49. Trendelenburg A. U., Limberger N., Starke K. Presynaptic alpha 2-autoreceptors in brain cortex: alpha 2D in the rat and alpha 2A in the rabbit. Naunyn Schmiedebergs Arch Pharmacol. 1993 Jul;348(1):35–45. doi: 10.1007/BF00168534. [DOI] [PubMed] [Google Scholar]
  50. Wada T., Fukuda N. Effects of DN-2327, a new anxiolytic, diazepam and buspirone on exploratory activity of the rat in an elevated plus-maze. Psychopharmacology (Berl) 1991;104(4):444–450. doi: 10.1007/BF02245647. [DOI] [PubMed] [Google Scholar]
  51. Wamsley J. K., Alburges M. E., Hunt M. A., Bylund D. B. Differential localization of alpha 2-adrenergic receptor subtypes in brain. Pharmacol Biochem Behav. 1992 Feb;41(2):267–273. doi: 10.1016/0091-3057(92)90097-y. [DOI] [PubMed] [Google Scholar]
  52. Winter J. C., Rabin R. A. Yohimbine as a serotonergic agent: evidence from receptor binding and drug discrimination. J Pharmacol Exp Ther. 1992 Nov;263(2):682–689. [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES